This week, these five stocks have the worst ratings in Sales Growth, one of the eight Fundamental Categories on Portfolio Grader.
Achillion (NASDAQ:ACHN) focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. ACHN also gets an F in Equity. For more information, get Portfolio Grader’s complete analysis of ACHN stock.
Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company which is focused on the discovery, development and commercialization of orally-administered, small molecule drugs known as pharmacological chaperones. FOLD gets F’s in Analyst Earnings Revisions, Equity, and Cash Flow as well. For more information, get Portfolio Grader’s complete analysis of FOLD stock.
Navidea Biopharmaceuticals (AMEX:NAVB) is focused on the development and commercialization of precision radiopharmaceutical diagnostics for diseases such as cancer. NAVB also gets F’s in Analyst Earnings Revisions, Equity, and Cash Flow. For more information, get Portfolio Grader’s complete analysis of NAVB stock.
Unwired Planet (NASDAQ:UPIP) provides open Internet-based communication infrastructure software and applications. UPIP also gets F’s in Earnings Growth, Analyst Earnings Revisions, Equity, Cash Flow, and Operating Margin Growth. For more information, get Portfolio Grader’s complete analysis of UPIP stock.
Ariad Pharmaceuticals (NASDAQ:ARIA) is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. ARIA also gets F’s in Earnings Growth and Equity. Shares of the stock have declined 2.9% since January 1. This is worse than the Nasdaq, which has seen a 1.2% increase over the same period. For more information, get Portfolio Grader’s complete analysis of ARIA stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
